EPS: As of FY2025 Q2, the actual value is USD -0.55.<h3>Financial Metrics</h3><h4>Operating Expenses</h4><ul><li>Research and Development Expense: For the three months ended June 30, 2025, research and development expenses were $4.0 million, an increase of $2.2 million compared to the same period in 2024. For the six months ended June 30, 2025, expenses were $6.0 million, an increase of $1.9 million compared to the same period in 2024.</li><li>General and Administrative Expense: For the three months ended June 30, 2025, general and administrative expenses were $0.5 million, a decrease of $0.7 million compared to the same period in 2024. For the six months ended June 30, 2025, expenses were $1.8 million, a decrease of $0.8 million compared to the same period in 2024.</li></ul><h4>Net Loss</h4><ul><li>Net Loss: For the three months ended June 30, 2025, the net loss was $4.6 million, an increase of $2.7 million compared to the same period in 2024. For the six months ended June 30, 2025, the net loss was $7.4 million, a decrease of $2.4 million compared to the same period in 2024.</li></ul><h4>Cash Flow</h4><ul><li>Net Cash Used in Operating Activities: For the six months ended June 30, 2025, net cash used in operating activities was $1.6 million, compared to $4.3 million for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: For the six months ended June 30, 2025, net cash provided by financing activities was $0.4 million, compared to $7.2 million for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Operational Pause: On June 24, 2025, Bio-Path Holdings, Inc. announced an operational pause to conserve capital, furloughing most employees while seeking financing or additional capital.</li><li>Clinical Trials: The company is focusing on the development of its lead drug candidate, Prexigebersen, in combination therapies for AML, with ongoing Phase 2 clinical trials.</li><li>Capital Requirements: The company expects to continue incurring significant operating expenses and requires substantial additional capital to fund its projected operating requirements.</li></ul>

Bio-Path | 10-Q: FY2025 Q2 EPS: USD -0.55